ENMD-1198

ENMD-1198

• CAS Number: 864668-87-1
• UNSPSC Description: ENMD-1198 (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-1198 is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization.
• Target Antigen: HIF/HIF Prolyl-Hydroxylase; Microtubule/Tubulin; STAT
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;Cytoskeleton;JAK/STAT Signaling;Metabolic Enzyme/Protease;Stem Cell/Wnt
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/ENMD-119.html
• Solubility: DMSO : 100 mg/mL (ultrasonic;warming)
• Smiles: C[C@@]12C=CC[C@@]1([H])[C@]3([H])CCC4=C(C=C(OC)C(C(N)=O)=C4)[C@@]3([H])CC2
• Molecular Weight: 311.42
• References & Citations: [1]Pasquier E, et al. ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010 May;9(5):1408-18.|[2]Snoeks TJ, et al. 2-methoxyestradiol analogue ENMD-1198 reduces breast cancer-induced osteolysis and tumor burden both in vitro and in vivo. Mol Cancer Ther. 2011 May;10(5):874-82.|[3]Moser C, et al. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer. 2008 Jul 23;8:206.
• Shipping Conditions: Room Temperature
• Clinical Information: Phase 1